RxDoctor Payments Data

Todd Schlossman, MD

Pulmonary Disease · Greenwood Village, CONPI 1558773713

Payments from drug & device makers

$1,332in general payments, 2019–2025

Across 57 payments — averaging $23.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$196
  • Mallinckrodt Hospital Products Inc.$194
  • GSK$112
  • Grifols USA, LLC$94
  • Insmed, Inc.$89
  • Sanofi$86
  • plus $562 from 16 others

What the payments were for

  • Food & beverage$1,22092%
  • Education$1128%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,332 in reported general payments places this provider in the 55th percentile of 248 pulmonary disease providers in Colorado.

See all pulmonary disease providers in Colorado

Medicare billing

Part B allowed, 2024
$100,512
Medicare patients
291
Services billed
854

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$82,865
Breztri AerosphereBudesonide/Glycopyr/Formoterol38$30,980
Spiriva RespimatTiotropium Bromide17$13,233
Breo ElliptaFluticasone/Vilanterol20$10,822
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$6,607
Fluticasone-SalmeterolFluticasone Propion/Salmeterol44$6,235
Arnuity ElliptaFluticasone Furoate13$4,840
SymbicortBudesonide/Formoterol Fumarate17$3,984
Albuterol Sulfate HfaAlbuterol Sulfate70$1,461
Mycophenolate Mofetil15$917
Omeprazole32$282
Montelukast Sodium21$92
Prednisone19$89
Furosemide26$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$112$98,527114 claims
AstraZenecaBreztri Aerosphere, Symbicort$196$34,96455 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$33$19,84029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 248 pulmonary disease providers in Colorado.

Other pulmonary disease in Greenwood Village

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →